The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alicia K. Morgans discussing ...

Progression-free survival on first subsequent therapy (i.e., PFS2) was significantly prolonged with both enzalutamide ...

In the exploratory subgroup analysis of chRCC by PD-L1 CPS status, there was a trend favoring nivolumab plus ipilimumab for ...

Dr. Simsek began by emphasizing that their group had previously shown that CD8+ T cells expressing PD-1 but lacking TIM-3 or LAG-3 are associated with improved clinical outcomes to anti–PD-1 ...

At the ESMO 2025 annual meeting, Dr. Hansen and colleagues presented the first-in-human data of 212 Pb-ADVC001 in patients ...

Cluster 4/5 was treated with the dual ICI regimen of ipilimumab plus nivolumab. This arm remains open to accrual. Clusters 3, 6, and 7 were excluded from the study. Additional secondary endpoints are ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany, was host to the Poster presentation session. Dr. Aaron Holmes presented the poster ...

Specific to patients with muscle invasive bladder cancer, improvement in disease free survival was also observed with ...

As an example, the ALPACA trial took 6.5 years to recruit just 25 patients across three Canadian centers, underscoring the ...

The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Maria De ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between September ...

The potent and selective HIF-2a inhibitor belzutifan is a treatment option for advanced RCC following prior anti-PD- (L)1 and VEGFR-TKI therapy and may be a highly suitable candidate for novel triplet ...